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Background: The late durability of endovascular aneurysm repair (EVAR) has been limited by progressive aortic
degeneration believed to be mediated by matrix metalloproteases (MMP). The goal of this study was to evaluate the effect
of a MMP inhibitor, doxycycline, on EVAR.
Methods: Patients undergoing EVAR were randomized to doxycycline (100 mg twice daily) or placebo for 6 months
following the procedure. Clinical data, blood samples, and computed tomography (CT) scans were obtained preopera-
tively, postoperatively (blood only), and at 1- and 6-month follow-up. Forty-four subjects were analyzed based on
intention-to-treat.
Results: Plasma MMP-9 decreased significantly below baseline in the doxycycline (N  20) treated patients at 6 months
(16.4%  20.7%, P < .05) while there was a nonsignificant increase in the placebo (N  24) group (128.1%  73.5%).
This was primarily related to changes between 1 and 6 months. In patients with endoleaks at 6 months, plasma MMP-9
increased in 83% of the placebo treated patients, but in only 14% of the doxycycline treated group (P < .03). Among
endoleak-free patients with AneuRx or Excluder endografts, doxycycline treatment resulted in greater decreases in
maximum aortic diameter than placebo treatment (13.3%  3.3% vs 3.8%  3.0%, P < .05). Furthermore, doxycycline
treatment significantly reduced the aortic neck dilatation at 6 months in Excluder treated patients.
Conclusion: There is evidence of persistent MMP release representing ongoing aortic degradation after endografting
which can be inhibited by doxycycline therapy. In analyses based on the endograft used, treatment with doxycycline also
demonstrated evidence of increased aortic dimensional stability, a surrogate marker for long-term success of EVAR.
Although encouraging, these results require confirmation in larger patient populations. Doxycycline should undergo
more thorough evaluation as a potential adjuvant treatment to improve the results of EVAR, particularly in certain
subgroups. ( J Vasc Surg 2008;48:519-26.)Abdominal aortic aneurysms (AAA) develop as a result
of arterial wall matrix degeneration, and pose a significant
risk for fatal rupture when the diameter exceeds 5.5 cm.
The development of endoluminal exclusion of abdominal
aortic aneurysms (EVAR) has become widely adopted as a
means of reducing the risk of aneurysm rupture, but late
loss of effective aneurysm exclusion and need for costly
follow-up and reintervention has tempered the enthusiasm
for the procedure.
Ongoing aortic wall degeneration and dilatation may
result in failure of AAA exclusion. Studies in human tissue
and animal models strongly suggest that enzymes of the
matrix metalloprotease (MMP) family play a central role in
the matrix degeneration of the aorta. There is evidence
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doi:10.1016/j.jvs.2008.03.064both in the animal model and in clinical trials that doxycy-
cline, a known metalloprotease inhibitor, can inhibit AAA
formation and progression.1-5
We hypothesized that the durability of endovascular
aneurysm repair might be improved by inhibiting the pro-
cess of aortic degeneration with adjuvant doxycycline ther-
apy. We designed this study to determine the short-term
effects of doxycycline on both radiographic and serologic
markers of aneurysm degeneration and endograft stability.
METHODS
Patient enrollment. Patients were consented and en-
rolled at the time of their clinic visit or admission to the
hospital for a planned EVAR under Institutional Review
Board (IRB) guidelines. The inclusion and exclusion crite-
ria are listed in Fig 1. Demographic, risk factor, and medi-
cation regimen data were obtained from the patient’s clin-
ical chart at the time of enrollment. Anticipated enrollment
was 76 patients.
Randomization and follow-up. Patients were ran-
domized to over encapsulated doxycycline therapy (100
mg taken twice daily) or a placebo which was identical in
physical appearance (size 00 capsules). Enrollment of
women and minorities was proportional to the frequency of
the disease in these populations. Randomization was per-
formed in the pharmacy utilizing a pre-assigned table of
codes. The patients received their first dose of study medi-
cation on the day following surgery and continued the
study therapy for 6 months. Clinical data and peripheral
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postoperatively, and at scheduled 1- and 6-month fol-
low-up visits. Cross-sectional imaging was obtained for all
patients preoperatively and at the 1- and 6-month fol-
low-up visits.
GI side effects occurred with similar frequency in both
the doxycycline (6) and placebo (4) treated patients, and
only one patient from each armwithdrew as a result of these
(P NS). Photosensitivity developed in significantly more
doxycycline treated patients (6 vs 0, P .01), however, was
not severe enough to cause study withdrawal in any of the
patients. One patient in the placebo group died of an
unrelated illness (pulmonary) during the study period.
Assays for circulating biomarkers. Serum and
plasma were separated into aliquots and stored at 80°C
until assayed. Measurements of the circulating biomarkers
were performed with commercially available assays for
plasma MMP-9, plasma MMP-2, serum IL-6, and serum
IL-8 (R&D Systems, Minneapolis, Minn). Analysis was
performed in a multiplex bead analysis format (Liquichip,
Qiagen, Valencia, Calif). We also measured C-reactive pro-
tein (CRP) using a highly-sensitive enzyme-linked immu-
nosorbent assay (ELISA) (hs-CRP, Bio-Check, Burlin-
game, Calif). The primary biomarker endpoint was the
change in plasma MMP-9 concentration at 6 months com-
pared with the baseline. Secondary endpoints evaluated
Fig 1. Study enrollment data. Inclusion and exclusion
study. During the first year of enrollment, the maxima
resulted in most of the anatomic exclusions. After random
four withdrawals: one developed a postoperative ileus and
abdominal aortic aneurysms (AAA) repair, and one p
medications after surgery and withdrew. After the me
without 6month follow-up. Two (1 doxycycline and 1 pl
(GI) side effects, 4 developed other illnesses and declin
reason, 1 person withdrew due to a change in insurance
placebo group died from complications of chronic obstr
could not contact and was lost to subsequent follow-up.were the change in circulating MMP-2, IL-6, IL-8 andCRP at 6 months compared with the baseline. Based on the
pattern of circulating proteases seen during analysis of the
data, we also elected to perform analysis of the effects of
doxycycline treatment on the interval assessments.
Analysis of imaging data. Data were collected from
the computed tomography (CT) scans, by individuals
blinded as to treatment group, regarding maximal aneu-
rysm diameter and transverse neck diameter at the level of
the most inferior renal artery and at 5 mm, 10 mm, and 15
mm below that level. The mean of these four diameters was
considered the neck diameter. “Centerline-of-flow” mea-
surements were used to assess these diameters when digital
data was available. All documented endoleaks and their
type were recorded. The primary imaging endpoint was the
change in maximal aortic diameter at 6 months. Secondary
analysis was performed on the percent graft oversizing at
the aortic neck and the presence or absence of endoleak at
6 months.
Statistical analysis. Data are reported as the mean 
standard error of the mean (SE). Power calculations were
performed a priori on the primary endpoints of MMP-9 for
circulating markers and maximum aneurysm diameter
which indicated analysis of about 40 individuals per group
would be necessary to have a -error of less than .1 with a
-error of less than .05. Data representing aortic diameters
and measured plasma and serum values were analyzed for
ria for enrollment are as listed at the conclusion of the
tic diameter necessary for enrollment was 5.0 cm; this
on, but before dispensing the study medications we had
unable to take the medication. One patient had an open
t from each group decided not to accept the study
ons were dispensed, we had an additional 11 patients
) patients withdrew claimingmedication gastrointestinal
urther participation, and 2 withdrew without stating a
rage and did not return to our facility, 1 patient in the
pulmonary disorder, and there was 1 patient whom wecrite
l aor
izati
was
atien
dicati
acebo
ed f
cove
uctivethe normality of the data distribution with the Shapiro-
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uted data sets (MMP-9, MMP-2, IL-6, IL-8, and CRP)
were performed on log transformations of those data
sets.6-8 Associations between plasma measurements and
aneurysm size were analyzed with Pearson correlation co-
efficients. Comparisons of means were performed with
one-way analysis of variance (ANOVA). Repeatedmeasures
multivariate analysis of variance (MANOVA) for change in
measurements over time were performed where appropri-
ate. The 2 test was used to compare categorical data
(Fisher exact test for average cell counts less than 5). A P
.05 was considered statistically significant.
We also identified unanticipated important effects on
the imaging endpoints based on the endograft device used
as well as the presence or absence of an endoleak. There-
fore, we performed post-hoc sub-group analyses of both
the primary and secondary endpoints by the endograft
device. Due to the small size of the female and minority
groups in this study, meaningful independent statistical
analysis of these groups was not informative.
RESULTS
Patient population and baseline studies. Patients
were enrolled over a 2-year period and evaluated at 1 and 6
months after elective placement of an aortic endograft for
an infrarenal AAA. Of the 59 patients who met the enroll-
ment criteria and were randomized into the study, 44
subjects had either imaging or plasma marker data available
at 6 months of follow-up and were included in the data
analyses (Fig 1). All patients with available data were ana-
lyzed by assigned treatment group regardless of compliance
with the medication regimen. The demographic charac-
teristics of those who were randomized and completed
follow-up are listed in Table I.
Although there were no significant differences between
Table I. Demographics of doxycycline treated and
control study populations
Doxycycline Placebo
P valuen  20 n  24
Age (y) 68.9  1.68 74.0  1.5 .0249
Gender (% males) 80% 79.2%
Body mass index (kg/m2) 29.6  1.5 27.5  0.8
Hypertension 18 (90%) 19 (79.2%)
Diabetes mellitus 2 (10%) 3 (12.5%)
Coronary disease 12 (60%) 11 (45.8%)
Inflammatory AAA 0 1 (4.2%)
Family history AAA 1 (5%) 3 (12.5%)
Peripheral vascular disease 8 (40%) 7 (29.2%)
Chronic obstructive
pulmonary disease 6 (30%) 10 (41.7%)
Current smoker 13 (65%) 7 (29.2%) .0324
Renal insufficiency 2 (10%) 6 (25%)
Intestinal bleed 4 (20%) 3 (12.5%)
Aortic diameter (mm) 57.2  2.1 57.2  2.4
Hemoglobin (g/dL) 13.9  0.5 13.9  0.3
Creatinine (mg/dL) 1.4  0.3 1.3  0.2doxycycline and placebo treated subjects in the distributionof most of the demographic features, the patients in the
doxycycline treatment group tended to be slightly younger
and were more likely to be current smokers at the time of
enrollment. Analysis of circulating markers and maximal
aneurysm size did not demonstrate any significant associa-
tion with either of these demographic features.
There was no significant difference in maximal aortic
diameter or the diameters of the aorta measured at the
“neck” of the aneurysm. There were also no differences in
preoperative circulating markers (Table II). As shown in
Fig 2, there was a significant positive correlation between
the preoperative maximum aortic diameter and the preop-
erative plasmaMMP-9 level (adj. R2 0.25, P .0003), as
well as a weak correlation with plasma MMP-2 (adj. R2 
0.08, P  .04). We saw no similar correlation between
aneurysm size and any of the other serologic markers
measured.
The device used for the endoluminal repair was left to
the discretion of the operating surgeon. Eight patients
(18.2%) were treated with an AneuRx endograft
(Medtronic, Minneapolis, Minn), 19 (43.2%) with Ex-
cluder (Gore, Flagstaff, Ariz) and 17 (38.6%) with Zenith
(Cook Medical, Bloomington, Ind). There were no signif-
icant differences in the device used and the baseline preop-
erative aortic measurements.
Procedural and periprocedural events. There were
no significant differences in the proximal nominal diameter
of the device used, procedural time, blood loss, or postop-
erative clinical laboratory values between the subjects ran-
domized to doxycycline or placebo (Table III). Four pa-
tients required hypogastric artery occlusion. Two patients
had a type II endoleak documented on the completion
arteriogram. There were no perioperative mortalities, and
one patient developed postoperative atrial fibrillation and
myocardial ischemia evidenced by an increase in troponin.
Compared with the baseline, on the day following
EVAR, we found that there were significant increases in
serum IL-8 (5.8  1.1 pg/ml vs 2.5  1.1 pg/ml, P 
.003), IL-6 (46.3  4.5 pg/ml vs 5.3  4.4 pg/ml, P 
Table II. Study parameters at baseline
Doxycycline Placebo
N  20 n  24
Aortic diameters (mm)
Maximum 57.2  2.1 57.2  2.4
At lowest renal artery 22.5  0.6 23.4  0.5
5 mm inferior 22.5  0.9 23.6  0.7
10 mm inferior 24.1  0.7 23.4  0.6
15 mm inferior 24.6  0.7 24.0  0.7
Circulating markers
(pg/mL)
MMP-9 45380  15238 57860  13910
MMP-2 199570  36919 211492  33702
IL-6 3.8  3.1 6.6  2.9
IL-8 1.9  1.1 3.0  1.0
CRP 56.0  13.3 47.5  12.2.0001), and CRP (137.9  12.5 pg/ml vs 51.4  12.3
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ng/ml vs 52.2  11.9 ng/ml, P  .06) did not quite reach
significance. There was no significant change in plasma
MMP-2 levels, and there was no correlation between aneu-
Fig 2. Correlation between pre-operative matrix metallopro-
teases (MMP)-9 and MMP-2 and maximum aortic diameter. Al-
though the adjusted correlation coefficient (adj. R2) for MMP-9 is
considerably greater than that for MMP-2, circulating levels of
both enzymes significantly correlate with the magnitude of aneu-
rysmal dilatation.
Table III. Procedural parameters and periprocedural
demographic data
Doxycycline Placebo
n  20 n  24
Hemoglobin
(g/dL) 11.7  0.4 11.1  0.3
Creatinine
(mg/dL) 1.3  0.3 1.2  0.3
Procedure time 2:44  0:16 3:05  0:16
Proximal device
diameter (mm) 27.4  0.4 26.4  0.6
Blood loss (mL) 350.0  64.0 406.3  51.6
Fluids (mL) 2400.0  209.1 2620.8  224.2
Device brand AneuRx  3 (15%) AneuRx  5 (20.8%)
Excluder  10 (50%) Excluder  9 (37.5%)
Zenith  7 (35%) Zenith  10 (41.7%)rysm size and postoperative plasmaMMP-9 orMMP-2 levels.Effect of doxycycline therapy on endoleak and max-
imum aortic diameter. For all patients, at 1 month, the
mean AAA size was 57.1 1.5 mm and the median change
in AAA diameter was 0.5 mm (mean: 0.02  0.6 mm). At
6months of follow-up, the meanmaximum diameter of the
AAA in the study was 52.6 1.7 mm. Overall, the median
absolute decrease in the aortic diameter at 6 months com-
pared with preoperatively was 2.6 mm (mean: 4.7 
1.0 mm, P  .0001), and compared with 1 month was
4.0 mm (mean: 4.8  0.8 mm, P  .0001). The
absolute changes in aortic diameter following endograft
placement were dependant on the initial aortic diameters
(adj. R2  0.34, P  .0005).9 At 1- and 6-month follow-
up, there were no identified type I, III, or IV endoleaks,
and there were 11 patients at 1 month and 12 patients at 6
months who had type II endoleaks identified.
When analyzed by treatment group, there was no sig-
nificant effect of doxycycline on the primary outcome mea-
sure of change in maximal aneurysm size between baseline
and 6-month measurements. There was also no effect of
doxycycline therapy on the presence of an endoleak at 6
months, one of our secondary outcome measures.
It has recently been demonstrated that aneurysm
shrinkage rates may be affected by the presence of an
endoleak or the specific endograft chosen which may have
obscured an effect of drug therapy.10 While our study was
underpowered to identify effects of these factors, device-
dependent differences in the maximal diameter change
between 1 and 6 months were consistent with published
comparisons,11 tending toward a greater decrease in AAA
diameter for those patients treated with a Zenith (Cook)
endograft (10.3%  2.5%) than those with an AneuRx
(Medtronic) (8.7%  3.4%) or Excluder (Gore) (6.7%
 2.2%, P  NS).
Based on these studies, we performed post-hoc sub-
group analysis, excluding patients with the Zenith en-
dograft or an endoleak at 6 months (Fig 3). We found that
between 1 and 6 months, the doxycycline treated patients
who had either an AneuRx or Excluder placed had signifi-
cantly greater decreases in aortic diameter than the pla-
cebo treated patients (13.3%  3.3% vs 3.8%  3.0%,
P  .05).
Effect of doxycycline therapy on aortic neck diam-
eters and graft migration. The aortic neck size was ex-
pressed as the percentage by which the nominal proximal
graft diameter exceeded the measured aortic diameter on
imaging. The mean oversizing of the endograft at baseline
overall was 15.2% and decreased to 8.3% at 6 months (P 
.0001). We found no difference in the planned oversizing
at baseline based on endograft used: 18.3% 1.5%, 16.5%
1.5%, and 12.6%  1.9% for the AneuRx, Zenith, and
Excluder grafts, respectively (P  NS).
There was no overall difference in change in the mean
graft oversizing at the aortic neck based on doxycycline
therapy. At 6 months, in the placebo group, relative resid-
ual oversizing had been reduced to 8.6%  3.1%, 7.6% 
2.2%, and 5.3% 3.3%, for AneuRx, Zenith, and Excluder
endografts, respectively. This represented a significant in-
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without any significant difference between devices. Among
the patients treated with doxycycline, there was an overall
significant increase in neck diameter over the course of the
study (P  .02), however, there was also a significant
difference based on the device used (P  .01). Specifically,
Fig 3. Effect of doxycycline treatment on maximal aneurysm
diameter change after endoluminal exclusion of an abdominal
aortic aneurysm. Change in maximal diameter was calculated as a
percentage change in the maximum infrarenal aortic diameter
between the 1 and 6 month computed tomography (CT) scans.
Patients with evidence of a type II endoleak on the 6-month CT
follow-up were excluded from this analysis. Doxycycline treatment
resulted in a significantly greater decrease in maximal aneurysm
size among the combined group of AneuRx and Excluder treated
patients (P  .05).
Fig 4. Effect of doxycycline treatment on aortic neck diameter
among patients with Excluder endograft. In the placebo treated
group all aortic necks significantly increased in diameter between
the preoperative and 6-month computed tomography (CT) scan
measures. Among the patients treated with an Excluder endograft,
doxycycline prevented this increase in aortic neck diameter. The
treated patients demonstrated a significantly smaller increase in
aortic diameter than the untreated patients for this sub-group (P
.05). Data is expressed as a percentage of the aortic neck diameter
as measured on cross-sectional imaging relative to the nominal
endograft diameter (percentage oversized).we found that there was no difference in the mean residualoversizing at 6 months between subjects treated with either
the Zenith (4.5% 2.9%) or AneuRx (6.3% 4.7%) grafts
but significantly less dilatation of the neck in the Excluder
treated patients (14.5%  1.8%, P  .04). Among the
individuals with an Excluder graft, there was a significant
increase in neck diameter by 6 months in the placebo
treated patients (P  .02), while there was no significant
difference between baseline and 6months with doxycycline
treatment (Fig 4).
No significant difference in the migration between the
different endograft devices or based on treatment group
was identified.
Effect of doxycycline therapy on plasma proteases.
The primary endpoint with respect to circulating biomark-
ers was achieved in the doxycycline treated group where
MMP-9 levels were found to decrease significantly from
preoperative levels (16.4% 20.7%, P .03) at 6months
(Fig 5). There was no significant difference between pre-
operative and 6-month MMP-9 levels among the placebo
treated patients (128.1%  73.5%).
Following the initial increase in levels the day following
endograft placement, there was an overall reduction in
mean plasma MMP-9 levels for all patients between post-
operative day 1 and 1 month (P  .0006). While between
1 and 6 months, the mean MMP-9 levels in the placebo
treated subjects significantly increased (206% 98.5%, P
.04), in the doxycycline treated subjects, the plasma
Fig 5. Effect of doxycycline therapy on the circulating levels of
matrix metalloproteases (MMP)-9. The mean levels of plasma
MMP-9 are plotted before and at all follow-up intervals after
placement of an aortic endograft. While the surgical procedure
caused an initial increase in plasma MMP-9, these levels decreased
over the first postoperative month in both groups. While plasma
MMP-9 subsequently increased by 6months in the placebo treated
patients, doxycycline treatment resulted in a continued decrease of
circulating MMP-9 in this interval. At 6 months, plasma MMP-9
decreased significantly below preoperative levels in the doxycycline
treated group (P  .03), but not in the placebo treated patients.
The overall change in MMP-9 during the study was significantly
different between treatment groups (P  .009).MMP-9 levels were stable or decreased (11.8%  12.5%,
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between treatment groups. Although there was a generally
positive correlation between the change in MMP-9 and the
change in aortic diameter, this was not statistically signifi-
cant.
In the placebo treated group, the presence of a type II
endoleak was associated with a greater likelihood of in-
creased plasma MMP-9 levels at 6 months compared with
the baseline in patients without an endoleak (83% vs 35%,
P .04). Treatment with doxycycline reduced the frequency
of increase in MMP-9 associated with an endoleak to 14%
(P  .03 vs placebo), which was similar to the incidence
without an endoleak (17%). Plasma MMP-2 levels, on the
other hand, showed no significant difference based on
treatment group or endoleak status and were stable
throughout the study period.
Effect of doxycycline on circulating inflammatory
markers. Following the acute postoperative increase, the
levels of IL-6, IL-8 and CRP all significantly decreased by 1
month. The serum levels of IL-6 and CRP were not signif-
icantly different than preoperative levels at both 1 month
(7.8  3.4 pg/ml and 76.8  11.5 pg/ml, respectively)
and 6 months (4.5  1.8 pg/ml, 51.1  8.0 pg/ml,
respectively), although the mean concentrations continued
to drop in that interval. This pattern was identical for the
doxycycline and placebo treated groups. The IL-8 levels
remained significantly elevated at 1 month compared with
preoperative levels (6.6  1.4 pg/ml, P  .02). By 6
months, the mean IL-8 levels were no longer significantly
different (4.5  1.2 pg/ml). The responses of the treated
and untreated patients were also similar with respect to
IL-8.
DISCUSSION
Endoluminal aneurysm repair relies on the radial force
of the stent against nondilated segments of aorta to main-
tain the proper apposition of the graft at its attachment
sites. The loss of close apposition can result in the develop-
ment of a leak into the aneurysm sac, repressurization of the
sac, and risk of rupture. Continued degeneration of the
proximal attachment site has been demonstrated after
EVAR and threatens the durability of the repair.12 Overall,
long-term follow-up has demonstrated the need for occa-
sional secondary interventions after EVAR, although the
frequency is likely shrinking due to modifications and im-
provements in endoluminal device design. Nevertheless, it
continues to be necessary to follow these patients with serial
imaging.13,14
Matrix degrading enzymes of the MMP group, and
especially MMP-9, are known to be present and active in
aneurysm wall.15 Two studies have demonstrated that
plasma MMP-9 is increased in the presence of an en-
doleak.8,16 It has been proposed that doxycycline therapy
may slow or halt the progression of small aneurysms be-
cause of its ability to inhibit enzymes of the MMP family.17
It currently is approved for use in gingivitis to reduce the
activity of these enzymes on periodontal tissues.18,19 Doxy-
cycline can inhibit aneurysm formation in animal mod-els,1-3 inhibit MMP activity and production in human
aneurysm tissue,4 and is well tolerated in patients with
AAA.5 An effective medical therapy, such as doxycycline,
has promise to reduce or eliminate secondary interventions
and thereby the need for imaging follow-up after endograft
placement, potentially improving the cost-effectiveness of
this procedure. This pilot study was designed to determine
whether doxycycline is an effective means to reduce circu-
lating MMP-9 levels and accelerate aneurysm shrinkage
following endografting.
In this study, the baseline levels of circulating MMP-9
were significantly correlated with aneurysm size, consistent
with prior observations.20 Like IL-6, IL-8, and CRP,
MMP-9 increased immediately following placement of the
endograft from an apparent generalized inflammatory re-
sponse which had essentially resolved by 1 month.21 Be-
tween 1 and 6 months following endograft placement the
natural history of the mean plasma MMP-9 in the placebo
treated patients was to increase. Remarkably, adjuvant ther-
apy with doxycycline prevented the increase during this
interval, and significantly reduced plasma MMP-9 below
preoperative levels at 6 months, one of the study’s primary
endpoints.
As expected, in our placebo treated patients, the pres-
ence of an endoleak resulted in increasing levels of circulat-
ing MMP-9 significantly more frequently than in endoleak
free patients. Treatment with doxycycline appeared to in-
hibit that effect, potentially signaling an inhibition of the
matrix degradation response to the pressurization of the
sac. Other markers of aneurysm degeneration including
CRP, IL-8, and IL-6 did not appear to be significantly
affected by doxycycline therapy.
The salutatory effects of doxycycline treatment on
plasma MMP-9 levels may imply beneficial effect on aneu-
rysm growth. However, none of the primary imaging end-
points was significantly affected by doxycycline treatment,
overall. This may have been due to a lack of power related
to not meeting our projected recruitment goals. There was
also unanticipated variation based on the specific endograft
placed.11 This study was not adequately powered to iden-
tify differences based on graft type.
We performed a post-hoc reanalysis of the data by
endograft, in particular examining the effects on the pa-
tients not treated with a Zenith endograft. In those
endoleak-free patients with either AneuRx or Excluder
grafts, the sac size decrease with doxycycline therapy was
significantly greater than placebo. This is encouraging,
albeit weak, evidence suggesting that the effects of doxycy-
cline on MMP-9 may be directly affecting the aneurysmal
dilatation.
Potentially of even more clinical significance, we also
found that doxycycline therapy can significantly reduce the
progressive dilatation of the aortic neck. Others have dem-
onstrated that progressive neck dilatation occurs after en-
dografting22 (and open repair23), is device dependent22
and is associated with risk of migration22 and endoleak.24
In this study, among the placebo-treated patients, there
was progressive dilatation of the proximal neck of the an-
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residual oversizing based on the nominal diameter of the
endograft. The inhibition of this progressive dilatation in
the Excluder patients treated with doxycycline may have
been a consequence of lower radial force in that graft,
allowing for small neck stabilization effects to be clinically
evident.
These findings suggest that protease activity within the
AAA wall continues despite endograft exclusion, and that
doxycycline therapy may inhibit this degenerative process.
The greatest response to doxycycline treatment was seen
with the placement of the Excluder where there was evi-
dence of accelerated aneurysm shrinkage and decreased
proximal neck dilatation. This may be partially related to
the covering material used with this endograft, which may
have transmitted more force to the aortic wall after graft
implantation.25 Prior studies have demonstrated decreased
aneurysm sac shrinkage and higher endoleak rates for this
endograft, and the covering of this endograft was subse-
quently modified to address this.26 However, there is evi-
dence that aneurysms treated with other endografts may
undergo similar changes albeit at a more prolonged inter-
val.13 Therefore, the beneficial effects of doxycycline ther-
apy seen prominently with the Excluder device in this short
studymay also have the potential to benefit the durability of
all endografts in the long term.
This trial is the first to use doxycycline in conjunction
with aortic endografting. Although the results are exciting,
there are many limitations of this study design including,
small size, single-institution enrollment, and short follow-
up. The limited enrollment resulted in a diminished ability
to assess our primary endpoints with adequate statistical
power. Althoughwe identified potentially important effects
of doxycycline on the plasma proteaseMMP-9, the physical
aneurysm effects demonstrated were based on post-hoc
sub-groups. The short follow-up did not allow us to eval-
uate the clinically meaningful endpoint of secondary inter-
ventions.
Overall, these results demonstrate that circulating
MMP-9 can be inhibited following endografting and that
this may result in improved endograft performance. This
study should serve as the basis for further well-controlled
and designed studies to improve the treatment of AAA.
The authors express their great appreciation for the
study coordination assistance provided by Sandy L. Dolan,
RN and the data organizational assistance provided by
Daniel Roshevsky, BA.
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Despite progressive improvement in endovascular device de-
sign and deployment techniques, a small but significant fraction of
post-endovascular aneurysm repair (EVAR) patients continue to
experience late aneurysm-related complications. In light of the
recent US Food and Drug Administration Public Health Notice
regarding increasing late aneurysm-relatedmortality following EVAR
(http://www.fda.gov/cdrh/safety/031808-medtronic.html), this
prospective, randomized trial of adjuvant doxycycline therapy to
improve procedural durability seems particularly timely. While
providing tantalizing insights into potential mechanisms of inter-
est, this study does not clarify the potential value of doxycycline as
either adjuvant or primary therapy for abdominal aortic aneurysm
(AAA) disease.
Primary study endpoints included (1) a reduction in plasma
matrix metalloproteinases (MMP)-9 levels with doxycycline
therapy and (2) a reduction in aneurysm sac size at 6 months.
Secondary endpoints included plasma MMP-2, serum IL-6,
IL-8, and highly-sensitive C-reactive protein (hs-CRP) levels
at 6 months. Of these, only plasma MMP-9 levels were noted
to decrease in doxycycline-treated patients between 1 and 6
months following EVAR. Doxycycline-induced reductions in
plasma MMP-9 levels did not translate into reduced AAA sac
size. While endograft-specific outcome analyses suggested evi-
dence of enhanced aneurysm sac and neck stability with doxy-
cycline, these were post-hoc analyses to be interpreted with
caution. These types of analyses are best used to generatePrior studies (including reference 16 of the article above) have
suggested that post-procedural plasma MMP levels are reduced
following either open surgical repair or EVAR, particularly in the
absence of endoleaks. In placebo treated patients in the current
series, interestingly, plasma MMP-9 levels actually rose slightly
following endografting. Why these plasma responses to EVAR
should differ between these series is unclear. This also highlights
the uncertain clinical relevance of reduced plasmaMMP-9 levels in
the absence of significant structural effects: in reference 5, plasma
MMP-9 levels were reduced following oral doxycycline therapy in
small AAA patients even though no influence was noted on ultra-
sound-determined diameter enlargement. Clearly more conclusive
data is needed, requiring much larger treatment groups appropri-
ately stratified by size, endoleak status, device type and exclusion
methodology (eg, uni-iliac vs bifurcated device, etc), thrombus
size and location and all other variables known or suspected to
influence late aneurysm remodeling and regression following
EVAR.
Most importantly this intriguing study underscores the
need for rigorous and fully-powered trials to test the ability of
doxycycline to suppress mural proteolysis in AAA, either follow-
ing EVAR or as primary therapy to limit progression of early
disease. More than 10 years after the original studies suggesting
potential efficacy, fully-funded clinical trials are long overdue
and clearly justified. Patients deserve to know whether or not
doxycycline therapy will reduce their risks of death and disability
from AAA disease.
